Royal Bank of Canada’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,612
| Closed | -$7K | – | 7585 |
|
|
2025
Q2 | $7K | Sell |
1,612
-98
| -6% | -$440 | ﹤0.01% | 6583 |
|
|
2025
Q1 | $7K | Sell |
1,710
-53,967
| -97% | -$313K | ﹤0.01% | 6279 |
|
|
2024
Q4 | $436K | Buy |
55,677
+45,327
| +438% | +$552K | ﹤0.01% | 4180 |
|
|
2024
Q3 | $136K | Buy |
10,350
+6,891
| +199% | +$87.4K | ﹤0.01% | 5129 |
|
|
2024
Q2 | $42K | Buy |
3,459
+2,622
| +313% | +$35.4K | ﹤0.01% | 5741 |
|
|
2024
Q1 | $13K | Sell |
837
-9,540
| -92% | -$129K | ﹤0.01% | 6112 |
|
|
2023
Q4 | $71K | Buy |
10,377
+4,910
| +90% | +$28.4K | ﹤0.01% | 5822 |
|
|
2023
Q3 | $30K | Buy |
5,467
+2,332
| +74% | +$13.6K | ﹤0.01% | 6032 |
|
|
2023
Q2 | $21K | Buy |
3,135
+1,056
| +51% | +$7.91K | ﹤0.01% | 6195 |
|
|
2023
Q1 | $10K | Sell |
2,079
-6,581
| -76% | -$26.9K | ﹤0.01% | 6340 |
|
|
2022
Q4 | $42K | Buy |
8,660
+2,844
| +49% | +$20.7K | ﹤0.01% | 5990 |
|
|
2022
Q3 | $84K | Buy |
5,816
+297
| +5% | +$4.92K | ﹤0.01% | 5432 |
|
|
2022
Q2 | $83K | Sell |
5,519
-3,952
| -42% | -$46.1K | ﹤0.01% | 5463 |
|
|
2022
Q1 | $113K | Sell |
9,471
-3,252
| -26% | -$33.4K | ﹤0.01% | 5565 |
|
|
2021
Q4 | $206K | Sell |
12,723
-2,837
| -18% | -$60.6K | ﹤0.01% | 5308 |
|
|
2021
Q3 | $444K | Buy |
15,560
+690
| +5% | +$21.7K | ﹤0.01% | 4467 |
|
|
2021
Q2 | $503K | Buy |
14,870
+5,564
| +60% | +$179K | ﹤0.01% | 4269 |
|
|
2021
Q1 | $282K | Buy |
9,306
+473
| +5% | +$19.4K | ﹤0.01% | 4667 |
|
|
2020
Q4 | $437K | Buy |
8,833
+1,394
| +19% | +$64.5K | ﹤0.01% | 4250 |
|
|
2020
Q3 | $286K | Buy |
7,439
+1,818
| +32% | +$72.4K | ﹤0.01% | 4286 |
|
|
2020
Q2 | $242K | Buy |
5,621
+5,505
| +4,746% | +$208K | ﹤0.01% | 4313 |
|
|
2020
Q1 | $3K | Sell |
116
-503
| -81% | -$14.6K | ﹤0.01% | 6221 |
|
|
2019
Q4 | $19K | Buy |
+619
| New | +$18.3K | ﹤0.01% | 5880 |
|
Other funds holding YMAB
Royal Bank of Canada's YMAB Position: Q3 2025 in Review
Royal Bank of Canada sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 1,612 shares — an estimated $7K sold.
Royal Bank of Canada first reported a position in YMAB in Q4 2019 and held it in 23 quarters. The position peaked at $503K in Q2 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Royal Bank of Canada reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Royal Bank of Canada sold 1,612 Y-mAbs Therapeutics shares in Q3 2025, an estimated $7K.
- Royal Bank of Canada first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 23 quarters.
- Royal Bank of Canada's Y-mAbs Therapeutics position peaked at $503K in Q2 2021.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Royal Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.